These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 12183857)
21. Prevalence and correlates of advanced retinopathy in a large selected hypertensive population. The Evaluation of Target Organ Damage in Hypertension (ETODH) study. Cuspidi C; Meani S; Valerio C; Fusi V; Catini E; Sala C; Magrini F; Zanchetti A Blood Press; 2005; 14(1):25-31. PubMed ID: 15823944 [TBL] [Abstract][Full Text] [Related]
22. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Gradman AH; Alfayoumi F Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048 [TBL] [Abstract][Full Text] [Related]
23. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372 [TBL] [Abstract][Full Text] [Related]
25. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353 [TBL] [Abstract][Full Text] [Related]
26. Prevalence and correlates of aortic root dilatation in patients with essential hypertension: relationship with cardiac and extracardiac target organ damage. Cuspidi C; Meani S; Fusi V; Valerio C; Sala C; Zanchetti A J Hypertens; 2006 Mar; 24(3):573-80. PubMed ID: 16467661 [TBL] [Abstract][Full Text] [Related]
27. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? Muxfeldt ES; Salles GF J Hypertens; 2008 May; 26(5):878-84. PubMed ID: 18398329 [TBL] [Abstract][Full Text] [Related]
28. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843 [TBL] [Abstract][Full Text] [Related]
29. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264 [TBL] [Abstract][Full Text] [Related]
30. Quinapril improves endothelial function in postmenopausal hypertensive patients. Farkas K; Fábián E; Nagy L Kidney Blood Press Res; 2008; 31(4):226-33. PubMed ID: 18587241 [TBL] [Abstract][Full Text] [Related]
31. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416 [TBL] [Abstract][Full Text] [Related]
33. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679 [TBL] [Abstract][Full Text] [Related]
34. [The organ damage in arterial hypertension]. Agabiti-Rosei E; Muiesan ML Ann Ital Med Int; 1995 Oct; 10 Suppl():99S-107S. PubMed ID: 8562278 [TBL] [Abstract][Full Text] [Related]
35. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Wachtell K; Papademetriou V; Smith G; Gerdts E; Dahlöf B; Engblom E; Aurigemma GP; Bella JN; Ibsen H; Rokkedal J; Devereux RB Am Heart J; 2004 Sep; 148(3):538-44. PubMed ID: 15389245 [TBL] [Abstract][Full Text] [Related]
36. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Su DF Curr Opin Cardiol; 2006 Sep; 21(5):486-91. PubMed ID: 16900013 [TBL] [Abstract][Full Text] [Related]
37. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Cuspidi C; Meani S; Valerio C; Sala C; Fusi V; Zanchetti A; Mancia G Am J Hypertens; 2007 Mar; 20(3):296-303. PubMed ID: 17324743 [TBL] [Abstract][Full Text] [Related]
39. The relationship between microalbuminuria, left ventricular hypertrophy, retinopathy, and sex hormone status in newly diagnosed hypertensive women. Apikoglu M; Bulucu F; Demirbas S; Ay SA; Karaman M; Altun B; Balta S; Gokce G; Demirkol S; Yaman H; Saglam K Clin Exp Hypertens; 2013; 35(5):325-9. PubMed ID: 22950595 [TBL] [Abstract][Full Text] [Related]
40. Target organ damage and associated clinical conditions among Nigerians with treated hypertension. Ayodele OE; Alebiosu CO; Salako BL; Awoden OG; Abigun AD Cardiovasc J S Afr; 2005; 16(2):89-93. PubMed ID: 15915275 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]